BROWSE

Related Scientist

Kim, Ho Min's photo.

Kim, Ho Min
단백질 커뮤니케이션 그룹
more info

ITEM VIEW & DOWNLOAD

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept

Cited 0 time in webofscience Cited 0 time in scopus
33 Viewed 0 Downloaded
Title
Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept
Author(s)
Hong, H.K.; Park, Y.J.; Kim, D.K.; Ryoo, N.-K.; Ko, Y.-J.; Park, K.H.; Ho Min Kim; Woo, S.J.
Subject
ENDOTHELIAL GROWTH-FACTOR, ; INDUCED CHOROIDAL NEOVASCULARIZATION, ; PROLIFERATIVE DIABETIC-RETINOPATHY, ; OXYGEN-INDUCED RETINOPATHY, ; RANDOMIZED CLINICAL-TRIAL, ; INTRAVITREAL AFLIBERCEPT, ; TUMOR ANGIOGENESIS, ; PANRETINAL PHOTOCOAGULATION, ; MACULAR DEGENERATION, ; RANIBIZUMAB
Publication Date
2020-11
Journal
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, v.61, no.13, pp.22
Publisher
ASSOC RESEARCH VISION OPHTHALMOLOGY INC
Abstract
PURPOSE. VEGF-Grab is a novel anti-vascular endothelial growth factor (VEGF) candidate drug with higher affinity to both VEGF and placental growth factor (PlGF) compared to aflibercept. We investigated the preclinical efficacy of VEGF-Grab for ophthalmic therapy and compared it to that of aflibercept. METHODS. The in vitro anti-VEGF efficacy of VEGF-Grab was determined using VEGF-induced cell proliferation/migration and tube formation assays. The in vivo antiangiogenic efficacy of intravitreal injection of either VEGF-Grab or aflibercept was evaluated using murine models of ocular angiogenesis: mouse oxygen-induced retinopathy (OIR) and rat laser-induced choroidal neovascularization (CNV). The in vivo retinal toxicity in the mouse eye resulting from the injection of either drug was evaluated with light and electron microscopy. RESULTS. VEGF-Grab showed greater inhibition of VEGF-induced cell proliferation/migration than aflibercept, but it showed comparable inhibition of tube formation in vitro. In the in vivo OIR model, VEGF-Grab showed a comparable suppression of retinal neovascularization compared to aflibercept. Additionally, VEGF-Grab showed an efficacy similar to that of aflibercept in terms of CNV inhibition in the laser-induced CNV model. Histology and transmission electron microscopy showed no significant signs of toxicity in the mouse retina at 7 and 30 days following the intravitreal injection of VEGF-Grab or aflibercept. CONCLUSIONS. Compared to aflibercept, VEGF-Grab presented comparable in vivo antiangiogenic efficacy and superior in vitro anti-VEGF activity. The retinal safety profiles were comparable for the two drugs. Considering its known higher binding affinity to VEGF and PlGF compared to aflibercept, VEGF-Grab could be a potential candidate drug for neovascular retinal diseases and an alternative to aflibercept.
URI
https://pr.ibs.re.kr/handle/8788114/7541
DOI
10.1167/iovs.61.13.22
ISSN
0146-0404
Appears in Collections:
Pioneer Research Center for Biomolecular and Cellular Structure(바이오분자 및 세포구조 연구단) > Protein Communication Group(단백질 커뮤니케이션 그룹) > 1. Journal Papers (저널논문)
Files in This Item:
There are no files associated with this item.

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse